Parenteral Drugs (India) (NSE:PDPL) EPS (Basic): ₹-25.61 (TTM As of Mar. 2022)


NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) EPS (Basic)?

Parenteral Drugs (India) NSE:PDPL 4 EPS (Basic) is ₹-25.61 as of Mar. 2022. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

Parenteral Drugs (India)'s basic earnings per share (Basic EPS) for the three months ended in Mar. 2022 was ₹7.99. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2022 was ₹-25.61.

Parenteral Drugs (India)'s EPS (Diluted) for the three months ended in Mar. 2022 was ₹7.99. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was ₹-25.61.

Parenteral Drugs (India)'s EPS without NRI for the three months ended in Mar. 2022 was ₹7.99. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2022 was -25.61.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Parenteral Drugs (India)  (NSE:PDPL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Parenteral Drugs (India) EPS (Basic) Related Terms

Parenteral Drugs (India) EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) EPS (Basic) Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -37.50 -49.61 -38.26 -40.82 -25.61

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.33 -10.74 -11.27 -11.58 7.99
NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Parenteral Drugs (India)'s Basic EPS for the fiscal year that ended in Mar. 2022 is calculated as

Basic EPS (A: Mar. 2022 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-763.619-0)/29.817
=-25.61

Parenteral Drugs (India)'s Basic EPS for the quarter that ended in Mar. 2022 is calculated as

Basic EPS (Q: Mar. 2022 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(238.129-0)/29.816
=7.99

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-25.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹-25.61 mean?
Parenteral Drugs (India) (NSE:PDPL) has a EPS (Basic) of ₹-25.61 as of Mar. 2022. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s EPS (Basic) too high?
Parenteral Drugs (India)'s current EPS (Basic) is ₹-25.61. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s EPS (Basic) compare to ZTS and CTLT?
Parenteral Drugs (India)'s EPS (Basic) of ₹-25.61 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current EPS (Basic) is ₹-25.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current EPS (Basic) of ₹-25.61. The current EPS (Basic) is ₹-25.61. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current EPS (Basic) is ₹-25.61 as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price